Abdominal Obesity: Clinical Trials

3 trials for Abdominal Obesity, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 completed, 1 unknown. 3 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 43Active not recruiting 1, Completed 1, Unknown 1

Follow Abdominal Obesity: new trials by email Literature Review of Abdominal Obesity trials Research Report on Abdominal Obesity

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus
Berberine plus lifestyle intervention, Placebo plus lifestyle intervention - PreDiabetes, Abdominal Obesity
Phase 4Active not recruitingChina National Center for Cardiovascular Diseases20242023-10-312025-12-31
The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension
Moxonidine, Irbesartan - Abdominal Obesity, Hypertension
Phase 4UnknownBaker Heart and Diabetes Institute1002012-01-012012-02-03
Treatment of Adiposity Related hypErTension (TARGET)
Aliskiren, Moxonidine, Hydrochlorothiazide - Hypertension, Abdominal Obesity
Phase 4CompletedUMC Utrecht322010-08-012012-02-24

Narrower conditions

Hypertension (3)  ·  Obesity, Abdominal (3)  ·  Atherosclerosis (1)  ·  Depression (1)  ·  Dyslipidemias (1)  ·  Metabolic Syndrome (1)  ·  Obesity (1)  ·  Prediabetic State (1)

Broader conditions

Body Weight (3)  ·  Cardiovascular Diseases (3)  ·  Nutrition Disorders (3)  ·  Nutritional and Metabolic Diseases (3)  ·  Overnutrition (3)  ·  Overweight (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Signs and Symptoms (3)  ·  Vascular Diseases (3)  ·  Glucose Metabolism Disorders (2)  ·  Metabolic Diseases (2)  ·  Obesity (2)  ·  Arterial Occlusive Diseases (1)  ·  Arteriosclerosis (1)  ·  Behavior (1)

Interventions

moxonidine (2)  ·  Berberine (1)  ·  Hydrochlorothiazide (1)  ·  Irbesartan (1)  ·  aliskiren (1)

Sponsors

Baker Heart and Diabetes Institute (1)  ·  China National Center for Cardiovascular Diseases (1)  ·  UMC Utrecht (1)

Countries

Australia (1)  ·  China (1)  ·  Netherlands (1)

Top investigators

Haibo Zhang, MD (1)  ·  Jing Li, PhD (1)  ·  W. Spiering, MD PhD (1)

Results publications

PMID 29085669